Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naive advanced ALK plus non-small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA study

被引：5
|
作者：
Zhou, C. [1 ]
Lu, Y. [2 ]
Kim, S-W. [3 ]
Baisamut , T. [4 ]
Zhou, J. [5 ]
Zhang, Y. [6 ]
He, J. [7 ]
Yang, J. [8 ]
Cheng, Y. [9 ]
Lee, S-H. [10 ]
Chang, J. [11 ]
Fang, J. [12 ]
Liu, Z. [13 ]
Bu, L. [14 ]
Qian, L. [15 ]
Xu, T. [15 ]
Archer, V. [16 ]
Hilton, M. [17 ]
Zhou, M. [18 ]
Zhang, L. [19 ]
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Thorac Oncol, Chengdu, Peoples R China
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[4] Mahidol Univ, Fac Med, Ramathibodi Hosp, Bangkok, Thailand
[5] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Resp Dis, Hangzhou, Peoples R China
[6] Zhejiang Canc Hosp, Dept Thorac Oncol, Hangzhou, Peoples R China
[7] Guangzhou Med Univ, Dept Thorac Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China
[8] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[9] Jilin Canc Hosp, Dept Oncol, Changchun, Peoples R China
[10] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[11] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Canc Hosp, Shenzhen, Peoples R China
[12] Peking Univ, Sch Oncol, Beijing Canc Hosp, Dept Thorac Oncol, Beijing, Peoples R China
[13] Capital Med Univ, Beijing Chest Hosp, Dept Oncol, Beijing, Peoples R China
[14] Roche Pharma Dev, Dept Data Sci, Shanghai, Peoples R China
[15] Roche Pharma Dev, Dept Clin Sci, Shanghai, Peoples R China
[16] Roche Prod Ltd, Prod Dev, Welwyn Garden City, Herts, England
[17] F Hoffmann La Roche Ltd, Prod Dev Data Sci, Basel, Switzerland
[18] Roche Pharma Dev, Dept Safety, Shanghai, Peoples R China
[19] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.353
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA11
引用
收藏
页码：S1563 / S1563
页数：1
相关论文
共 50 条
  • [1] Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naive ALK plus advanced non-small-cell lung cancer (NSCLC)
    Zhou, C.
    Lu, Y.
    Kim, S-W.
    Reungwetwattana, T.
    Zhou, J.
    Zhang, Y.
    He, J.
    Yang, J-J.
    Cheng, Y.
    Lee, S. H.
    Bu, L.
    Xu, T.
    Yang, L.
    Wang, C.
    Morcos, P. N.
    Mitry, E.
    Li, Z.
    ANNALS OF ONCOLOGY, 2018, 29 : 174 - 174
  • [2] ALESIA 7-year update: Alectinib vs crizotinib in Asian patients (pts) with treatment-naive advanced ALK plus nonsmall cell lung cancer (NSCLC)
    Zhou, C.
    Lu, Y.
    Kim, S-W.
    Baisamut, T. R.
    Zhou, J.
    Zhang, Y.
    He, J.
    Yang, J-J.
    Cheng, Y.
    Lee, S-H.
    Chang, J.
    Fang, J.
    Liu, Z.
    Bu, L.
    Qian, L.
    Archer, V. R.
    Zhou, M.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S1634 - S1635
  • [3] Alectinib (ALC) vs crizotinib (CRZ) in treatment-naive ALK plus non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study
    Mok, T. S. K.
    Peters, S.
    Camidge, D. R.
    Ou, S-H I.
    Ahn, J. S.
    Tan, E. H.
    Li, Z.
    Lee, J-S.
    Cho, B. C.
    Geater, S. L.
    Sriuranpong, V.
    Ho, J.
    Chan, O. S-H
    Zeaiter, A.
    Balas, B.
    Nueesch, E.
    Mitry, E.
    Morcos, P. N.
    Kim, D-W.
    ANNALS OF ONCOLOGY, 2017, 28 : 191 - 191
  • [4] Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naive ALK plus advanced NSCLC
    Zhou, C.
    Lu, Y.
    Kim, S-W.
    Reungwetwattana, T.
    Zhou, J.
    Zhang, Y.
    He, J.
    Yang, J. J.
    Cheng, Y.
    Lee, S. H.
    Bu, L.
    Xu, T.
    Yang, L.
    Wang, C.
    Morcos, P. N.
    Mitry, E.
    Liu, T.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2018, 29 : 740 - 740
  • [5] Resistance mechanisms to lorlatinib or crizotinib in treatment-naive patients (pts) with ALK plus advanced non-small cell lung cancer (NSCLC)
    Felip, E.
    Martini, J-F.
    Mazieres, J.
    Kim, D-W.
    Shepard, D.
    Polli, A.
    Liu, G.
    de Marinis, F.
    Toffalorio, F.
    Goto, Y.
    Solomon, B.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1014 - S1014
  • [6] Phase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)
    Popat, S.
    Liu, G.
    Lu, S.
    Song, G.
    Samnotra, V.
    Yang, J. C-H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [7] Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK plus NSCLC): Primary Results from Phase III Study (J-ALEX)
    Kim, Young
    Hida, Toyoaki
    Nokihara, Hiroshi
    Kondo, Masashi
    Azuma, Koichi
    Seto, Takashi
    Takiguchi, Yuichi
    Nishio, Makoto
    Yoshioka, Hiroshige
    Imamura, Fumio
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Kuriki, Hiroshi
    Asabe, Ryoichi
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S378 - S379
  • [8] Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study
    Shaw, Alice Tsang
    Peters, Solange
    Mok, Tony
    Gadgeel, Shirish M.
    Ahn, Jin Seok
    Ou, Sai-Hong Ignatius
    Pero, Maurice
    Dziadziuszko, Rafal
    Kim, Dong-Wan
    Rosell, Rafael
    Zeaiter, Ali Hassan
    Liu, Ting
    Golding, Sophie
    Balas, Bogdana
    Noe, Johannes
    Morcos, Peter N.
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK plus NSCLC).
    Seto, Takashi
    Nishio, Makoto
    Hida, Toyoaki
    Nokihara, Hiroshi
    Morise, Masahiro
    Kim, Young Hak
    Azuma, Koichi
    Takiguchi, Yuichi
    Yoshioka, Hiroshige
    Kumagai, Toru
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Satouchi, Miyako
    Kozuki, Toshiyuki
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Asakawa, Takashi
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK plus NSCLC).
    Yoshioka, Hiroshige
    Hida, Toyoaki
    Nokihara, Hiroshi
    Morise, Masahiro
    Kim, Young Hak
    Azuma, Koichi
    Seto, Takashi
    Takiguchi, Yuichi
    Nishio, Makoto
    Kumagai, Toru
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Satouchi, Miyako
    Kozuki, Toshiyuki
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Yoshimoto, Takuya
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345